Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
The algorithm provides automated assessments of objective and reproducible scanned slide images that can help with diagnosis and targeted treatment options.
The technology from Scanwell is also being used for its at-home SARS-CoV-2 antibody test, which is under development and awaiting Emergency Use Authorization.
The firm's OpsisDx platform uses a glass slide with hydrogel structures to bind molecules in urine and create a colorimetric signature reflecting biofluid changes.
Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
